Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of TCR² Therapeutics Inc. (NASDAQ: TCRR) to Adaptimmune Therapeutics plc for 1.5117 Adaptimmune ADS for each TCR² share is fair to TCR² shareholders. Following the closing of the transaction, TCR² stockholders will own approximately 25% of the combined company.

Halper Sadeh encourages TCR² shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether TCR² and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for TCR² shareholders; (2) determine whether Adaptimmune is underpaying for TCR²; and (3) disclose all material information necessary for TCR² shareholders to adequately assess and value the merger consideration. On behalf of TCR² shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages TCR² shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005534/en/